The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment

Pirogovsky, Eva; Schiehser, Dawn M.; Litvan, Irene; Obtera, Kristalyn M.; Burke, Mathes M.; Lessig, Stephanie; Song, David; Liu, Lin; Filoteo, J. Vincent

doi:10.1016/j.parkreldis.2014.03.010

Cited by 39 publications

(34 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When screening and diagnostic cutoffs are overlapping, the czDRS-2 may be considered as suitable abbreviated assessment tool at Level I. Our results go beyond other comparable studies that have measured the contribution of the DRS to the detection of PD-MCI, as the present study clearly shows a better discriminatory potential of the czDRS-2 in the diagnosis of PD-MCI versus HC [12] and a comparable discriminatory potential for PD-MCI versus PD-NI [13]. …”

Section: Discussionsupporting

confidence: 65%

“…The results of the MDS PD-MCI battery at Level II that was used in differentiating PD-MCI from HC and PD-MCI from PD-NI are presented in table 3. After establishing a diagnosis of PD-MCI, we determined the discriminatory potential of the czDRS-2 total score and subscales in differentiating PD-MCI from paired HC and concomitantly PD-MCI from PD-NI (following the approach of Pirogovsky et al [13]). A ROC curve analysis yielded an AUC of 84% (95% CI 75-93) for the czDRS-2 total score (PD-MCI vs. HC) and an AUC of 82% (95% CI 73-91) for the czDRS-2 total score (PD-MCI vs. PD-NI).…”

Section: Resultsmentioning

confidence: 99%

“…For diagnostic purposes, the most recent study recommends a cutoff value of ≤140 for screening and of ≤137 in the detection of PD-MCI. However, the former study [12] did not use the current PD-MCI Level II MDS criteria for the diagnosis of PD-MCI, while the latter study [13] did not use a control sample. The principal goals of the present study were to (1) provide a normative data set for the Czech version of the DRS-2 (czDRS-2) in the Czech population stratified by age and education [10], (2) to show the discriminatory potential of the czDRS-2 in PD-MCI based on Level II MDS criteria in comparison to HC and patients with PD-NI (PD with no cognitive impairment at Level II) [11], and (3) to determine the sensitivity, specificity and optimal cutoff scores in the diagnosis of PD-MCI in the Czech population, thus delimitating the construct equivalence of the method and its diagnostic validity in a different cultural setting [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data

Bezdíček¹,

Michalec

Nikolai³

et al. 2015

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: The aim of the present study was to provide normative data and determine the validity of the Czech version of the Mattis Dementia Rating Scale 2 (czDRS-2) in screening for mild cognitive impairment in Parkinson's disease (PD-MCI) based on the Movement Disorder Society (MDS) Level II criteria. Methods: For validation purposes, 41 healthy controls (HC), 46 patients with PD-NI (Parkinson's disease, no impairment) and 41 patients with PD-MCI (all groups assessed by the MDS Level II criteria for PD-MCI) were matched according to age and education. Results: With screening and diagnostic cutoff scores determined at ≤139 points, the czDRS-2 showed a sensitivity of 78% and a specificity of 88% in the detection of PD-MCI versus HC and a sensitivity of 78% and a specificity of 76% in the detection of PD-MCI versus PD-NI. The AUC (95% confidence interval) for the czDRS-2 was 84% (75-93) and 82% (73-91), respectively. We report percentile values for 286 subjects from the Czech population stratified by education level. Conclusion: Our results show that the czDRS-2 is a valid instrument at Level I for screening PD-MCI and support its construct validity and diagnostic equivalence in a cross-cultural setting.

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data

Bezdíček¹,

Michalec

Nikolai³

et al. 2015

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…Data for participants needing additional symptomatic therapy before 44 weeks were imputed for the primary analysis, but these participants continued to be followed for secondary analyses. Secondary outcome measures were the change in individual parts of the UPDRS, change in ambulatory capacity, 21 change in Schwab and England Activities of Daily Living (SEADL) scale, 22 change in Parkinson's Disease Questionnaire 39 (PDQ-39), 23 change in Mattis Dementia Rating Scale (DRS), 24 and change in the Geriatric Depression Scale (GDS-15). 25 Secondary measures of safety and tolerability were the proportion of participants who completed the study on their assigned dose of study drug, the adverse event frequency and severity, changes in vital signs, and clinical laboratory values.…”

Section: Methodsmentioning

confidence: 99%

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

2015

The Lancet Neurology

225

View full text Add to dashboard Cite

Summary Background A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease in a multicentre, double-blind, placebo-controlled, futility clinical trial. Methods Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1 mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day pioglitazone, 45 mg/day pioglitazone, or placebo. Investigators were masked to the treatment assignment. Only the statistical centre and the central pharmacy knew the treatment name associated with the randomisation number. The primary outcome was the change in the total Unified Parkinson's Disease Rating Scale (UPDRS) score between the baseline and 44 weeks, analysed by intention to treat. The primary null hypothesis for each dose group was that the mean change in UPDRS was 3 points less than the mean change in the placebo group. The alternative hypothesis (of futility) was that pioglitazone is not meaningfully different from placebo. We rejected the null if there was significant evidence of futility at the one-sided alpha level of 0.10. The study is registered at ClinicalTrials.gov, number NCT01280123. Findings 210 patients from 35 sites in the USA were enrolled between May 10, 2011, and July 31, 2013. The primary analysis included 72 patients in the 15 mg group, 67 in the 45 mg group, and 71 in the placebo group. The mean total UPDRS change at 44 weeks was 4.42 (95% CI 2.55–6.28) for 15 mg pioglitazone, 5.13 (95% CI 3.17–7.08) for 45 mg pioglitazone, and 6.25 (95% CI 4.35–8.15) for placebo (higher change scores are worse). The mean difference between the 15 mg and placebo groups was −1.83 (80% CI −3.56 to −0.10) and the null hypothesis could not be rejected (p=0.19). The mean difference between the 45 mg and placebo groups was −1.12 (80% CI −2.93 to 0.69) and the null hypothesis was rejected in favour of futility (p=0.09). Planned sensitivity analyses of the primary outcome, using last value carried forward (LVCF) to handle missing data and using the completers' only sample, suggested that the 15 mg dose is also futile (p=0.09 for LVCF, p=0.09 for completers) but failed to reject the null hypothesis for the 45 mg dose (p=0.12 for LVCF, p=0.19 for completers). Six serious adverse events occurred in the 15 mg group, nine in the 45 mg group, and three in the placebo group; none were thought to be definitely or probably related to the study interventions. Interpretation These findings suggest that pioglitazone at the doses studied here is unlikely to modify progression in early Parkinson's disease. Further study of pioglitazone in a larger trial in patients with Parkinson's disease is not recommended. Funding National Institute of Neurological Disorders and Stroke.

show abstract

“…Az MDRS-re vonatkozó nemzetközi vizsgálatok szerint a PD-MCI 138-140 közötti határértékekkel azonosítható [43,44,45], míg a PDD 123-132 ponttal [28,44,45]. A magyar PD-populáción meghatározott vágó-értékek is ebbe a tartományba esnek: 138,5-139,5, illetve 128,5-131,5 az iskolázottságtól függően (2. táblá-zat).…”

Section: öSszefoglaló Közleményunclassified

Neurokognitív zavarok diagnosztizálási és kezelési lehetőségei Parkinson-kórban

et al. 2015

View full text Add to dashboard Cite

A jelen tudományos közleményt a szerzők a Pécsi Tudományegyetem alapításának 650. évfordulójának szentelik.Az összefoglaló közleményben a szerzők részletesen bemutatják a Parkinson-kórhoz társuló neurokognitív zavarok jellegzetességeit, felmérésük lehetséges módjait és kezelési lehetőségeit. A neurokognitív zavarok meghatározását sokáig nehezítette a diagnosztikai kritériumrendszerek sokszínűsége. Az Amerikai Pszichiátriai Társaság által a Mentális Rendellenességek Kórmeghatározó és Statisztikai Kézikönyvének ötödik átdolgozása (Diagnostic and Statistical Manual of Mental Disorders, DSM-5) magával hozta a major és az enyhe neurokognitív zavar megnevezéseket a demencia és az enyhe kognitív zavar fogalmát helyettesítendően. A DSM-5 neurokognitív zavarra vonatkozó defi ní-ciói a klinikumban jól alkalmazhatóak, ám szükségessé vált a leggyakrabban használt szűrőtesztek, úgymint a Mini

show abstract

The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment

Cited by 39 publications

References 15 publications

Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data

Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

Neurokognitív zavarok diagnosztizálási és kezelési lehetőségei Parkinson-kórban

Contact Info

Product

Resources

About